Just kidding. No, I didn't. That guy's an idiot. We'll be at $40 by the summer.
Well, his last message yesterday said that that you probably only have one or two days to buy shares before a big move up, so technically, he still isn't wrong. He also never suggested that his price target would hit immediately after the move up. I'd say waiting until the end of March is fair before claiming he is ultimately wrong or right.
Check out ARWR, REGN, GILD, CELG, NLNK, and more importantly, the IBB which is down 2%. Not much if it's an individual stock, but when you're talking about the entire sector, that's pretty significant.
Not all biotechs follow the direction of the IBB, but most do. If they didn't, the IBB wouldn't be red.
See, the problem with posts like this is that people like to point out when Bud is "wrong" (which you can't really say at this point because he's not giving one-day price projections), yet rarely do people point out when he is right. Just think if you're going to point out one, you should point out the other. I'm wagering that he'll be proven right at some point this month.
Yes, I would say that makes you an idiot. (No offense.) If the stock tanks on bad news Monday, you probably won't feel too great about yourself. I own a few shares as a gamble, and I'll be happy if it works out, but I also won't feel defeated if it doesn't.
Very nice to see this letter. Kudos to Pat Furlong for doing this. I hope it eases some of the animosity that has been occurring.
Not really. The entire biotech sector is getting absolutely pummeled today. This isn't specific to SRPT. The big biotechs can weather the storm much better, but spec biotechs always take the biggest beating.
Don't completely agree. DMD is a terminal illness that kills boys quickly, so the populist point of view is much more warranted and hard to negate than it would be for something more benign. I don't think there's a legit concern that if they listen to the wishes of DMD advocates that they'd be under pressure to cave for something such as an osteoarthritis drug.
I'm not saying that RTRX is a bad stock to own. It's not, and it has plenty more to move, but I do find Martin's strategy a bit too intentionally pumpy. It just leaves a bad taste in my mouth. I guess it's better than putting out baloney press releases though. And I do wish the company success since they are targeting diseases that badly need options.
Well, you could argue that there is a placebo effect short term. But you can't really argue that there's a placebo effect after two years. Or if you do, then you're an idiot.
This FDA needs to go and take Eric Hoffman with them.
You're like the annoying kid in middle school that nobody liked. My hunch is that you have very few friends in real life and have to pay women to have secks.
Well stated grey. I'm glad the parents have taken the gloves off and are calling out the FDA for the schmucks they are. Being nice and agreeable doesn't work with them apparently.